Organoids - Market Insights, Competitive Landscape, and Market Forecast - 2030

Organoids - Market Insights, Competitive Landscape, and Market Forecast - 2030

Organoids Market By Product Type (Pancreas, Intestine, Lung, Liver, Neural, And Others), Source (Pluripotent Stem Cells (Hipscs), And Adult Stem Cells (Ascs), Application (Disease Pathology, Regenerative Medicine, Drug Testing, Drug Discovery And Personalized Medicine, And Others), End-User (Hospitals And Diagnostic Centers, Biotechnology And Pharmaceutical Industry, Academic And Research Institutes, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to rise in the preference for personalized medicines and the growing uses of organoids in cancer research

The global organoids market is estimated to grow at a CAGR of 13.53% during the forecast period from 2024 to 2030. The demand for Organoids is primarily being boosted owing to the rise in the preference for personalized medicines, the growing use of organoids as potential alternatives for animal testing procedures, and its growing use in cancer research, among others during the forecast period from 2024 to 2030.

Organoids Market Dynamics:

One of the major factor influencing the growth of the Organoids market is the rise in the preference for personalized medicines across the globe. This is potentially due to the increasing prevalence of tailored therapies.

The National Center of Biotechnology Information estimated in 2020 that there are approximately 21 organoid clinical trials underway worldwide, and that number is expected to rise in the years to come due to advancements in science and improvements in infrastructure. Furthermore, the worldwide organoids market is anticipated to rise as a result of the growing usage of organoid technology for a variety of applications, such as genetic mutation, gene assessment, and tumor modeling.

Organoid culture makes it possible to directly and simultaneously expand diseased and matched normal cells from individual patients, facilitating the creation of a living tumor organoid biobank and its possible use in customized therapy.

For instance, it has been discovered that HBV infection in PSC-derived liver organoids could reproduce the life cycle of HBV and HBV-induced hepatic dysfunction, indicating that PSC-derived liver organoids may provide a promising personalized infection model for the development of personalized hepatitis treatment.

Therefore, in the coming years, the use of organoids is expected to increase in the evaluation of various diseases through the use of personalized medicines developed by organoid technology. Thus, the increasing patient population suffering from various diseases globally is thereby expected to increase the preference for personalized medicines, which is anticipated to propel the overall market growth of the Organoids market during the forecast period from 2024 to 2030.

However, limitations associated with the use of organoids, lack of high-fidelity cell types, and the limited maturation associated with organoids may act as significant restraints that are expected to limit the growth of the Organoids market during the forecast period.

Organoids Market Segment Analysis:

Organoids market by Product Type (Pancreas, Intestine, Lung, Liver, Neural, and Others), Source (Pluripotent Stem Cells (Hipscs) and Adult Stem Cells (Ascs), Application (Disease Pathology, Regenerative Medicine, Drug Testing, Drug Discovery, and Personalized Medicine, and Others), End-User (Hospitals and Diagnostic Centers, Biotechnology and Pharmaceutical Industry, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the Organoids market, the liver category is estimated to amass a significant revenue share in the Organoids market in 2023. This can be attributed to the various characteristics and the research applications offered by liver organoids, which are expected to increase the demand for the same.

Hepatic organoids are functioning three-dimensional (3D) in vitro models of the liver that serve as a new platform for investigating hepatic development and regeneration, detoxification and metabolism, liver disease modeling, and adult stem cell biology.

Hepatic organoids allow scientists to study their specific research issues in a physiologically appropriate context by providing an in vitro system that closely resembles an in vivo setting. A greater understanding of hepatic regenerative mechanisms, as well as the creation of in vitro systems that replicate hepatocyte proliferation and differentiation, will pave the way for autologous cell treatment and transplantation in the upcoming years. The generation of hepatic organoids from patients with inherited liver disease also allows for the development of drug-screening platforms and toxicity assays for customized therapy, as well as deeper investigation of the signaling pathways implicated in the underlying disease.

Genome editing methods, along with the liver organoid culture platform, enable the restoration of genetically repaired stem cells into afflicted patients, where they can develop into healthy hepatocytes capable of performing wild-type functions.

Thus, all the above-mentioned factors are likely to propel the demand for liver organoids in the Organoids market during the given forecast period from 2024 to 2030.

North America Is Expected To Dominate The Overall Organoids Market:

North America is expected to account for the highest proportion of the Organoids Market in 2023, out of all regions. This is due to the presence of several pharmaceutical and biotechnology companies that use organoid 3D culture technology to develop regenerative medicines for drug discovery & development in North America. In addition, the growing focus on R&D activities by key manufacturers, and rising clinical and research initiatives in the region are the factors responsible for the growth of the North America Organoids market.

For example, leading biopharmaceutical businesses in the US are concentrating on growing their product offerings across many distribution channels in diverse nations throughout the world. To enhance their industrial research operations, certain US corporations are focusing on direct collaboration with university institutions.

The presence of key players in the US such as Thermo Fisher Scientific, BioIVT, ZenBio, Corning Incorporated, Organovo, among others are focusing on evolving and expanding their product range by introducing new inventive items to the worldwide market.

In July 2023, the California headquartered company, Molecular Devices, LLC., a leading high-performance life science solutions provider, continued industrializing biology with the latest launch of its organoid line expansion to support next-generation drug discovery.

The offering leveraged proprietary bioreactor and bioprocess technology to scale up the production of standardized, assay-ready organoids originating from customer-supplied organoid lines or patient-derived xenografts (PDX).

Thus, all the above-mentioned factors are likely to increase the market for Organoids in the North American region during the given forecast period from 2024 to 2030.

Organoids Market Key Players:

Some of the key market players operating in the Organoids market include Thermofisher Scientific Inc., StemCell Technologies Inc., Qgel, DefiniGE, Cellesce Ltd, OcellO B.V., Hubrecht Organoid Technology (HUB), Organovo Holdings Inc., Takara Bio Inc., Corning Incorporated, and others.

Recent Developmental Activities In The Organoids Market:

In February 2024, ATCC and Tissue Dynamics, a disruptive pharma-tech company integrating advanced artificial intelligence tools with bionic human organoids, announced a partnership to develop workflow-friendly cardiac organoids-based kits for improved cardiac safety testing in drug development. The collaboration was done under the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) framework.

In February 2023, TheWell Bioscience launched a newly engineered cell harvesting solution to recover organoids and cells faster with higher efficiency. The VitroGel® Organoid Recovery Solution could recover organoids from both animal-based extracellular matrix (ECM) and synthetic VitroGel hydrogels.

In March 2021, Bio-Techne released its new Cultrex UltiMatrix Reduced Growth Factor Basement Membrane Extract (RGF BME) to support organoid and pluripotent stem cell cultures, which is an extracellular-matrix hydrogel to be used during the culturing of organoids and pluripotent stem cells. The product addressed the need for a dependable, high-concentration cell-scaffolding matrix with compositional and physical properties specifically designed for use in generating 2D and 3D cell culture models.

Key Takeaways From The Organoids Market Report Study

Market size analysis for current Organoids Market size (2023), and market forecast for 6 years (2024 to 2030)

Top key product offerings, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global Organoids market.

Various opportunities available for the other competitors in the Organoids Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Organoids market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Organoids market growth in the coming future?

Target Audience Who Can Be Benefited From This Organoids Market Report Study

Organoids product providers

Public and Private Corporate companies

Organoids-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Product Providers dealing in Organoids

Various corporates who want to know more about the Organoids Market and the latest product offerings in the Organoids Market.

Frequently Asked Questions For The Organoids Market:

1. What are organoids?

Organoids are 3D cell cultures derived from pluripotent stem cells that mimic the structure, function, and cellular complexity of human organs. These miniaturized versions of organs are especially valuable for studying complex multicellular organ structures like the brain, retina, kidney, and lungs. Organoids are used to model organ development and disease, offering researchers the ability to study patient-specific genetics, cell organization, and tissue-like structures in vitro.

2. What is the market for Organoids?

The global organoids market is estimated to grow at a CAGR of 13.53% during the forecast period from 2024 to 2030.

3. What are the drivers for the Global Organoids market?

The Organoids Market is slated to witness prosperity owing to rise in the preference for personalized medicines, growing use of organoids as potential alternative for animal testing procedures, its growing use in cancer research, among others during the forecast period from 2024 to 2030.

4. Who are the key players operating in the global Organoids market?

Some of the key market players operating in the Organoids market include Thermofisher Scientific Inc., StemCell Technologies Inc., Qgel, DefiniGE, Cellesce Ltd, OcellO B.V., Hubrecht Organoid Technology (HUB), Organovo Holdings Inc., Takara Bio Inc., Corning Incorporated, and others.

5. Which region has the highest share in the Global Organoids market?

North America is expected to dominate the overall Organoids market during the forecast period from 2024 to 2030. This is due to the presence of several pharmaceutical and biotechnology companies that use organoid 3D culture technology to develop regenerative medicines for drug discovery & development in North America. In addition, the growing focus on R&D activities by key manufacturers, rising clinical and research initiatives in the region are the factors responsible for the growth of the North America Organoids market.